E Fund Management Co. Ltd. Buys 2,748 Shares of Amgen Inc. (NASDAQ:AMGN)

E Fund Management Co. Ltd. raised its stake in Amgen Inc. (NASDAQ:AMGN) by 28.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 12,382 shares of the medical research company’s stock after purchasing an additional 2,748 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Amgen were worth $3,227,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in Amgen in the 3rd quarter valued at $25,000. Centricity Wealth Management LLC bought a new stake in Amgen in the 4th quarter valued at $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the 3rd quarter valued at $29,000. Synergy Investment Management LLC bought a new stake in Amgen in the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC bought a new stake in Amgen in the 4th quarter valued at $36,000. 76.50% of the stock is currently owned by institutional investors.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David M. Reese sold 8,711 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the sale, the executive vice president now directly owns 62,147 shares of the company’s stock, valued at $18,222,743.34. The trade was a 12.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of a number of research reports. Leerink Partners reduced their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Bank of America boosted their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday. Finally, Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus price target of $314.95.

Amgen Price Performance

Amgen stock opened at $317.82 on Friday. The stock has a market cap of $170.73 billion, a price-to-earnings ratio of 42.10, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm has a 50-day moving average of $284.89 and a two-hundred day moving average of $299.91.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.00%. Amgen’s dividend payout ratio (DPR) is 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.